Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

(2015) Jeffrey R. Infante et al.   INVESTIGATIONAL NEW DRUGS

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

(2014) Ramon Salazar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

(2013) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

(2013) S. E. Pratt et al.   CLINICAL CANCER RESEARCH

Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population

(2013) Sandhya N. Iyer et al.   GENE

Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

(2013) S. E. Pratt et al.   MOLECULAR CANCER THERAPEUTICS

Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications

(2012) Elodie Moysan et al.   MOLECULAR PHARMACEUTICS

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2011) Stijn L.W. Koolen et al.   CLINICAL CANCER RESEARCH

A User's Guide to the Encyclopedia of DNA Elements (ENCODE)

(2011)   PLOS BIOLOGY

Quantification of Gemcitabine Incorporation into Human DNA by LC/MS/MS as a Surrogate Measure for Target Engagement

(2010) Enaksha R. Wickremsinhe et al.   ANALYTICAL CHEMISTRY

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

(2010) Luigi De Petris et al.   EUROPEAN JOURNAL OF CANCER

Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

(2010) Stig Linder et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine

(2009) David M. Bender et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

(2008) S. A. Veltkamp et al.   CLINICAL CANCER RESEARCH